Below are several biotech companies in the news you should know
HENDERSON, NV / ACCESSWIRE / February 12, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue. The company traded above $3 dollars last year before hitting lows with the rest of the biotech industry. The company has started to rally in lockstep with the industry's ETF: IBB and could be on the verge of a breakout that may send BRTX above their 2018 highs. Get a jumpstart on the crowd by researching BRTX today.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), Immunomedics, Inc. (NASDAQ: IMMU) and INSYS Therapeutics, Inc. (INSY).
According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.
One of the more novel approaches to fighting this obesity epidemic is being developed by BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.875M, Share Price: $0.748), a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
_____
Sangamo Therapeutics, Inc. (SGMO) (Market Cap: $849.414M, Share Price: $8.32) recently reported preliminary molecular and enzymatic evidence of editing of the human genome in vivo (inside the body). These findings are part of the interim results from the Phase 1/2 CHAMPIONS Study evaluating SB-913, a zinc finger nuclease (ZFN) in vivo genome editing product candidate for the treatment of patients with Mucopolysaccharidosis Type II (MPS II).
_____
Arrowhead Pharmaceuticals, Inc. (ARWR) (Market Cap: $1.594B, Share Price: $16.92) reported fiscal first-quarter net income of $12 million, after reporting a loss in the same period a year earlier.
On a per-share basis, the Pasadena, California-based company said it had net income of 13 cents.
_____
Immunomedics, Inc. (IMMU) (Market Cap: $2.652B, Share Price: $13.93) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
_____
INSYS Therapeutics, Inc. (INSY) (Market Cap: $326.044M, Share Price: $4.39) announced positive results from its dose-finding pharmacokinetic ("PK") study - INS015-18-124 -evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan's MYL EpiPen as well as Par Pharmaceuticals' Adrenalin (epinephrine injection).
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: Microcap Speculators